Platform in Medical Technology

Unlikely Treatment Identified by BrainCells Neurogenesis Platform Improved Clinical Outcomes in Patients Suffering From Depression

SAN DIEGO, July 27 /PRNewswire/ -- BrainCells Inc., a company leading the scientific research of neurogenesis using its proprietary platform technology to identify novel pathways for the treatment of central nervous system (CNS) diseases, announced today results from the first cli...

OmegaGenesis Unveils Novel Nanotechnology Platform With Broad Biomedical Applications

New Company Founded on Mayo Clinic Discoveries is Developing Therapies for Wounds, Diabetic Foot Ulcers and Hair Growth Using Nano-Materials with Angiogenic Properties GILROY, Calif., Dec. 15 /PRNewswire/ -- OmegaGenesis today unveiled the company's novel technology platform which employs...

Modigene Platform Validated in Independent Phase III Trial of CTP Technology

- Validates the Clinical Utility of Modigene's CTP Technology for Extending the Duration of Action of Therapeutic Proteins - NES-ZIONA, Israel, July 10 /PRNewswire-FirstCall/ -- Modigene Inc., (OTC Bulletin Board: MODG) today noted the successful completion of a Phase III clinical tri...

Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH

SAN DIEGO, June 25 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL ) today announced that the company has successfully completed first-year milestones under a three-year, $6.0 million grant awarded in 2007, and is advancing with the development of a DNA vaccine manufacturing proces...

Canopus BioPharma Strengthens its CB1400 Platform Technology for Mucositis and Oncology Treatments Through License Agreement With Wisconsin Alumni Research Foundation

LOS ANGELES, California, June 18 /PRNewswire-FirstCall/ -- Canopus BioPharma, Inc. (OTC: CBIA), a biotechnology company developing pharmaceutical products and assay methods for patients suffering from infectious disease, radiation sickness, cancer and addiction, today announced the signing of ...

GeneGo is Awarded NCI Grant for Development of Systems Biology Platform for Integrative Data Analysis in Cancer

ST. JOSEPH, Mich., June 17 /PRNewswire/ -- GeneGo, Inc., a leading provider of databases, software and services in systems biology, announced today that they were awarded a Phase I SBIR from National Cancer Institute (NCI) for the development of a platform for functional data analysis in cance...

Study Shows Intradigm's RNAi Nanoplex Technology To Be Effective Systemic siRNA Delivery Platform for the Treatment of Various Cancer Models

Findings Support Gene-Silencing Mechanism and Demonstrate Significant Tumor Growth Inhibition Across Multiple Tumor Models in Mice PALO ALTO, Calif., April 14 /PRNewswire/ -- Intradigm Corporation, a leading developer of targeted, systemic RNA interference (RNAi) therapeutics, today anno...

Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research

BETHESDA, Md., March 18 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, announced that five posters will be presented on April 14, 2008, at the ann...

Syndicom SpineConnect Web Platform Chosen for Applied Spine's Leg and Back Pain Clinical Trial of Its Stabilimax NZ(R) Dynamic Spine Stabilization System

Better collaboration and surgeon-to-surgeon communication leads to more accurate clinical trial results in Stabilimax NZ study DURANGO, Colo. and NEW HAVEN, Conn., Sept. 18 /PRNewswire/ -- Syndicom, the premier developer of collaborative innovation networks, today announced that the co...

Trana Discovery and Southern Research Institute Announce the First RNA-RNA High Throughput Drug Screening Assay Platform for HIV Antivirals

Collaboration validates unique HIV assay system that identifies potential tRNA inhibitors CARY, N.C. and BIRMINGHAM, Ala., Sept. 17 /PRNewswire-USNewswire/ -- Trana Discovery, a drug discovery company, today announced the development of a high throughput screening (HT...

Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases

-Acquisition of Pacific Pharma Technologies Brings Proprietary Artificial Intelligence-Based Drug Discovery Platform and Novel Drug Candidates to Upstream- -Initial Compounds Demonstrate Promising In Vitro Activity Against Devastating Parasitic Diseases Affect...

ExonHit Reports Proof-of-Concept in Breast Cancer Diagnostic Using its SpliceArray(TM) Platform

PARIS, March 16 /PRNewswire-FirstCall/ -- ExonHit Therapeutics (Alternext: ALEHT) today reported the publication in Lancet Oncology of a study conducted by Institut Gustave Roussy, which describes the identification of a deregulated cell function in breast cancer through the analysis of altern...

AMT Obtains License to Amgen's GDNF Gene to Develop Treatment for Parkinson's Disease with AMT's Proprietary Gene Therapy Platform

AMSTERDAM, The Netherlands, September 18 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that it obtained a license from Amgen to use their GDNF gene for the development of a gene therapy treatment for Par...

Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug Delivery Platform

ORMD 0901 is Being Developed as an Oral Dosage Form of a GLP1-analog Aimed at Improving Glycemic Control in Adults With Type 2 Diabetes JERUSALEM, Israel, September 16 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB), a developer of oral drug delivery systems, announ...

AlphaVax Continues to Expand the Use of Its Vaccine Platform

RESEARCH TRIANGLE PARK, N.C., June 6 /PRNewswire/ -- AlphaVax, Inc. recently received notification from the National Institute of Allergies and Infectious Diseases (NIAID), one of the granting institutes of the National Institutes of Health (NIH), that it has been awarded a second grant to con...

Presentation of Data on Progen's Cancer Epigenetic Targets Platform

BRISBANE, Australia, May 30 /PRNewswire-FirstCall/ -- (ASX: PGL; Nasdaq: PGLA) New data on Progen's cancer epigenetic targets program will be presented tomorrow at the American Association for Cancer Research (AACR) Epigenetics Meeting in Boston by Progen's collaborators at the Johns Hopkins U...

Inclinix Announces New Patent for Expert System Platform

WILMINGTON, N.C., March 10 /PRNewswire/ -- Inclinix, Inc., an enrollment contract research organization (CRO) and provider of clinical trial recruitment solutions, announced today that it has received a patent for its Expert System Platform (ESP). ESP is a software system that guides interview...

AVEO Pharmaceuticals Novel Oncology Research Platform and Clinical Pipeline to Be Featured at AACR

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 12, 2007 - AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel, targeted cancer medicines, announced today that it will present a total of 12 oral and poster presentations at the American Association for Ca...

Abraxis BioScience Presents Pre-Clinical Findings That Support Role of SPARC Expression in Cancer and the Role of the Nanoparticle Albumin Bound (nab) Technology Platform in Targeting the Pathway

LOS ANGELES--(BUSINESS WIRE)--Apr 19, 2007 - Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global biopharmaceutical company, announced results from two pre-clinical studies that support the role of SPARC (secreted protein acidic and rich in cysteine) expression in cancer and Abraxis' nanop...

Materia Licenses Metathesis Catalyst Platform to Eisai

PASADENA, Calif.--(BUSINESS WIRE)--Jun 20, 2007 - Materia, Inc., a catalyst technology company, announced today the licensing of its metathesis platform to Eisai Co., Ltd., a leading Japanese pharmaceutical company, for use in drug discovery and development. The non-exclusive license agreement prov...

The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece

BRUSSELS, Belgium and KOS, Greece, June 29, 2007 /PRNewswire/ -- The European Myeloma Platform (EMP) says updated data for previously treated patients on REVLIMID (lenalidomide) plus the steroid dexamethasone shows median survival of 35 months, nearly three years. The data are pooled from two larg...

Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform

HAMBURG, Germany, May 03, 2007 /PRNewswire/ -- At the April AACR Annual Meeting, Indivumed presented data which provide a sound scientific basis for a new drug test-platform to predict drug response in patients. Tumor tissue-derived primary cell lines are currently the first choice for cancer dr...

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

...both cases excluding non-cash stock compensation expense. "Our strong financial performance is a direct result of the success of our technology platform and business strategy. We and our partners are advancing our large and growing pipeline of 19 drugs in development. Our partnership strategy not onl...

NewCardio Announces Master Services Agreement With Dedicated Phase I

...TM) solution. NewCardio's innovative 3D ECG platform technology dramatically improves the accuracy and ...ompany focused on the development of a proprietary platform technology to provide higher accuracy to, and incr...der development. NewCardio's three-dimensional ECG platform is designed to reduce the time and expense involve...

2,500 Cases Completed With the Magnetic Irrigated Catheter

...theter has broadened the capabilities of the Stereotaxis system, further demonstrating the potential of our remote magnetic navigation technology as a platform for all manner of cardiac and vascular interventions," said Michael P. Kaminski, Stereotaxis President and CEO. "Stereotaxis labs are quickly becoming...

Nektar Therapeutics Reports Second Quarter 2009 Financial Results

...ults for Oral NKTR-118, its proprietary novel peripheral opioid antagonist that combines Nektar's advanced small molecule polymer conjugate technology platform with naloxol, a derivative of the opioid-antagonist drug, naloxone. Nektar's technology has been shown to increase oral bioavailability and inhibit pe...

Debiopharm Group and Mercury Therapeutics, Inc. Sign an Exclusive License Agreement for the Development and Commercialisation of Debio 0930

...ncer and cardiovascular disease. Mercury is focusing its internal AMPK drug development program for indications in oncology. Mercury's lead generation platform is based on a proprietary technology that enables the discovery and development of novel compounds that directly activate AMPK, a key regulator of who...

Medigus and Tower Semiconductor Announce World's Smallest Medical Video Camera Based on Advanced CMOS Image Sensor

...d using Medigus' electronic, optic and integration platform technologies. The camera features dedicated bio-co... western world. Medigus has an advanced technology platform that includes the necessary elements for developing a wide range of endoscopic procedures. The platform includes various CCD and CMOS video cameras develo...

FDA Advisory Committee Votes in Favor of SAPHRIS(R) (asenapine) for Acute Bipolar I Disorder and Acute Schizophrenia

... with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription, animal health and consumer health care products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, pati...

First Skin Cancer Patients Treated With Electronic Brachytherapy (eBx) At University of Wisconsin Riverview Cancer Center

...erapy is indicated, including IORT (intraoperative radiation therapy). As a platform technology, the Axxent System is designed to deliver non-radioactive therap...o a broader spectrum of patients and their physicians. The Axxent treatment platform provides a therapeutic dose of radiation directly to the region at risk wit...

Researchers Create First Targeted Knockout Rats Using Zinc Finger Nuclease Technology

...sted our time and resources to develop the CompoZr platform because we see enormous potential in a technology ... developing a new, fully human monoclonal antibody platform based on transgenic rats. The rat is a widely used...enesis and hybridoma technologies. OMT's antibody platform is the result of an improved understanding of B-ce...

Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma

...s with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription, animal health and consumer health care products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patie...

CareFirst BCBS Covers eNO Measurement for Diagnosis, Asthma Treatment

...a simple-to-use, non-invasive monitor for the measurement of exhaled nitric oxide (eNO) for the management of asthma. The Apieron biosensor technology platform utilizes a patented technology that allows for the highly sensitive detection of selected analytes like eNO. Apieron is committed to collaborating wit...

Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease; Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver Disease and Metabolic Syndrome

...cacious pharmaceutical with the safety of a natural dietary carotenoid." About Cardax Pharmaceuticals. Cardax Pharmaceuticals is developing a platform of proprietary, exceptionally safe, small molecule compounds that impact inflammation driven by mitochondrial oxidative stress. The Company's first pr...

AlphaVax Announces Results from Initial Testing of Its H1N1 (Swine) Influenza Vaccine

...r just a single inoculation. "Our vaccine platform provides several potential advantages over other i... company that uses a proprietary alphavirus vector platform technology that has proven to be highly flexible a...ness strategy is to maximize the potential of this platform through a mixture of in-house and partnered progra...

Cognition Therapeutics Closes Series A Financing to Advance Drug Candidates for Alzheimer's Disease

...diseases. These assays emphasize phenotypic or functional responses of mature primary neurons to the toxic proteins. Cognition's proprietary chemistry platform converts natural products into low molecular weight chemically stable druglike molecules, and is thus a source of novel pharmacophores and valuable dr...

Velos, Inc. Releases Software to Support Cancer Centers With New Workflow and Content for NCI Clinical Trials Reporting Program

...cer Institute (NCI) Clinical Trials Reporting Program, (CTRP). Velos has proactively developed these capabilities and functions in its Velos eResearch platform to ease and streamline registration of interventional trials. The content, based on specifications published for the CTRP, delivers capabilities for c...

Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks

...blished and well-characterized therapeutic agents. The company is using its platform delivery technology, named Fluidosomes(TM) technology, for the development ...nous to the lung that are formulated into small liposomes. This nanocapsule platform offers wide-ranging potential for unmet medical needs, including chronic re...

Schering-Plough Expands Vicriviroc Phase II Study in Treatment-Naive Patients With HIV

... with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doc...

Elbit Imaging Ltd. Announces - Swiss Team Uses InSightec's ExAblate(R) 4000 Brain System to Treat Patients With Functional Brain Disorders

...ntrol and adjust the treatment in real time to ensure that the targeted area is fully treated and surrounding tissue is spared. The ExAblate 4000 is a platform for a variety of transcranial indications, such as brain tumors, functional neurosurgery, stroke and targeted drug delivery. The ExAblate(R) 20...